- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of neurokinin-1 receptor antagonists
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 12, Issue 5, Pages 673-685
Publisher
Informa Healthcare
Online
2013-05-25
DOI
10.1517/14740338.2013.804059
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevention of Nausea and Vomiting Associated with Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used with Highly Emetogenic Preparative Regimens
- (2012) Patrick J. Stiff et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
- (2012) Da Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy
- (2012) F. Longo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder
- (2012) David Michelson et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review
- (2012) L. V. dos Santos et al. JNCI-Journal of the National Cancer Institute
- Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study
- (2012) Daniele Santini et al. LANCET ONCOLOGY
- Rolapitant for the Prevention of Postoperative Nausea and Vomiting
- (2011) Tong J. Gan et al. ANESTHESIA AND ANALGESIA
- Casopitant and Ondansetron for Postoperative Nausea and Vomiting Prevention in Women at High Risk for Emesis
- (2011) ron Altorjay ARCHIVES OF SURGERY
- Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
- (2011) F. D. Rodriguez et al. CURRENT MEDICINAL CHEMISTRY
- NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
- (2011) M. Munoz et al. CURRENT MEDICINAL CHEMISTRY
- Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting
- (2011) Christina H Ruhlmann et al. Expert Opinion On Drug Safety
- Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
- (2011) H. F. Gao et al. INTERNAL MEDICINE JOURNAL
- Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
- (2011) Steven Grunberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects
- (2011) Thomas C. Marbury et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
- (2011) Joseph S. Bubalo et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder
- (2011) Emiliangelo Ratti et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults
- (2011) Pablo Tebas et al. PLoS One
- Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting
- (2011) Paul J. Hesketh et al. SUPPORTIVE CARE IN CANCER
- Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis
- (2011) Yan Jin et al. SUPPORTIVE CARE IN CANCER
- Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial
- (2011) Muneer H Abidi et al. SUPPORTIVE CARE IN CANCER
- A Triple-Drug Combination to Prevent Nausea and Vomiting Following BEAM Chemotherapy Before Autologous Hematopoietic Stem Cell Transplantation
- (2011) W. Pielichowski et al. TRANSPLANTATION PROCEEDINGS
- Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals
- (2010) Mark M Manak et al. AIDS
- A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans
- (2010) J. L. MADSEN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A Comparison of the Combination of Aprepitant and Dexamethasone Versus the Combination of Ondansetron and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy
- (2010) Ashraf S. Habib et al. ANESTHESIA AND ANALGESIA
- Phase II Study to Evaluate the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist Casopitant (GW679769) Administered with Ondansetron for the Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients
- (2010) Neil K. Singla et al. ANESTHESIOLOGY
- The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
- (2010) K Jordan et al. BONE MARROW TRANSPLANTATION
- The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma
- (2010) Gerlinde Egerer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
- (2010) Uday B. Dandamudi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients
- (2010) Toshiaki Takahashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat
- (2010) Mikhail Kalinichev et al. EPILEPSIA
- A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial
- (2010) Sanjay J. Mathew et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist
- (2010) John W. Bauman et al. INVESTIGATIONAL NEW DRUGS
- Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin-1 Receptor Antagonist
- (2010) Brendan M. Johnson et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder
- (2010) Tara L. Frenkl et al. JOURNAL OF UROLOGY
- The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
- (2010) Miguel Muñoz et al. LABORATORY INVESTIGATION
- Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
- (2010) Sonja Ständer et al. PLoS One
- Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy
- (2010) Flavia Longo et al. SUPPORTIVE CARE IN CANCER
- Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects
- (2009) Thomas C. Marbury et al. ANESTHESIA AND ANALGESIA
- Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting
- (2009) F. Roila et al. ANNALS OF ONCOLOGY
- Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
- (2009) Wichit Arpornwirat et al. CANCER
- Aprepitant
- (2009) Monique P. Curran et al. DRUGS
- The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
- (2009) Miguel Muñoz et al. INVESTIGATIONAL NEW DRUGS
- Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
- (2009) Jørn Herrstedt et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2009) Steven M Grunberg et al. LANCET ONCOLOGY
- Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
- (2009) Brendan Johnson et al. SUPPORTIVE CARE IN CANCER
- Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting
- (2008) Jon D. Herrington et al. CANCER
- Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability
- (2008) Lia Gore et al. PEDIATRIC BLOOD & CANCER
- Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism
- (2008) D. T. George et al. SCIENCE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started